Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESGO 2021 | Improving immunotherapy outcomes in ovarian cancer

Eric Pujade-Lauraine, MD, PhD, Hôpital Hôtel-Dieu, Paris, France, outlines approaches to improve outcomes in patients with ovarian cancer treated with immune checkpoint inhibitors, including combinations with chemotherapy as well as bevacizumab. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.